SETD7 promotes metastasis of triple-negative breast cancer by YY1 lysine methylation

Lili Gao,Junzhe Zhang,Qianqian Long,Yang Yang,Yiming Li,Guoqiang Li,Peng Pu,Shanshi Tong,Yamin He,Qing Li,Yang Chen,Yingbin Liu,Xianming Kong
DOI: https://doi.org/10.1016/j.bbadis.2023.166780
IF: 6.633
2023-01-01
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Abstract:Breast cancer has gradually become the predominant cause for cancer-associated death in women. The metastatic dissemination and underlying mechanisms of triple-negative breast cancer (TNBC) are not sufficiently understood. (Su(var)3-9, enhancer of zeste, Trithorax) domain-containing protein 7 (SETD7) is vital for promoting the metastasis of TNBC, as demonstrated in this study. Clinical outcomes were significantly worse in primary metastatic TNBC with upregulated SETD7. Overexpression of SETD7 in vitro and in vivo promotes migration of TNBC cells. Two highly conserved lysine (K) residues K173 and K411 of Yin Yang 1 (YY1) are methylated by SETD7. Further, we found that SETD7-mediated K173 residue methylation protects YY1 from the ubiquitin-proteasome degradation. Mechanistically, it was found that the SETD7/YY1 axis regulates epithelial-mesenchymal transition (EMT) and tumor cell migration via the ERK/MAPK pathway in TNBC. The findings indicated that TNBC metastasis is driven by a novel pathway, which may be a promising target for advanced TNBC treatment.
What problem does this paper attempt to address?